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BRINGING STANDARDS TO LIFE: SYNTHETIC 
BIOLOGY STANDARDS AND INTELLECTUAL 
PROPERTY 
Andrew W. Torrance† & Linda J. Kahl†† 
Abstract 
In aspiring to become a true engineering discipline for the 
biological sciences, the field of synthetic biology has a unique 
opportunity to create and encourage the widespread adoption of 
standards to enhance innovation and social impact in the field.  This 
article presents a study of the standards setting efforts by the 
institutions, firms, governments, and individuals within the field of 
synthetic biology. 
Numerous standards have been proposed in synthetic biology, 
including those relevant to structure, function, description, 
measurement, data, information exchange, software, biosafety and 
biosecurity, and even law.  At the present time, the adoption of 
technical standards has been relatively modest and no one technical 
standard appears to have dominated the field.  Standards covering 
policies in biosecurity, by comparison, are more firmly established 
and biosecurity practices governing commercial orders for synthetic 
DNA have been widely adopted. 
Among standards-setting groups within the synthetic biology 
community, most have expressed a preference that standards remain 
open and accessible to the community as a whole.  Recent 
developments, including the U.S. Supreme Court’s decision in AMP 
v. Myriad and the Leahy-Smith America’s Invents Act, could help give 
greater clarity to the scope of patent rights covering innovations and 
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standards in synthetic biology.  Copyright and trademark may 
provide alternatives mechanisms for conferring rights in synthetic 
biology inventions, setting and reinforcing standards, or promoting 
open innovation. 
Whether formal policies requiring the disclosure and licensing of 
property rights covering technical standards could be made 
mandatory or would ultimately be beneficial to the field of synthetic 
biology remain open questions.  What is certain is that the synthetic 
biology community is unusually attuned to debates surrounding 
intellectual property and standards setting, and views its engagement 
in these debates as vital to ensure the continued success of synthetic 
biology. 
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INTRODUCTION 
In his 1958 Nobel Prize acceptance speech, Edward Tatum 
described the application of biology as “the improvement of all living 
organisms by processes which we might call biological engineering.”1  
“Synthetic biology” has emerged over the past decade as a 
presumptive heir to Tatum’s vision.  Synthetic biology has developed 
two broad emphases.
2
  One involves the synthesis of large DNA 
molecules of specified nucleotide sequence.  A competitive industry 
of gene synthesis companies has emerged to synthesize made-to-order 
DNA molecules on a commercial scale, and speed and cost 
improvements of DNA synthesis are making this technology 
increasingly accessible.  The second emphasis involves the design and 
implementation of genetic circuits constructed from basic genetic 
components.  A distinct feature of synthetic biology is its conscious 
reliance on engineering approaches.
3
  In fact, influences from 
engineering, as well as computer science, have led to more 
consideration of standards setting, interoperability, and 
interchangeability in synthetic biology than is usual in other areas of 
biology.  Many in the synthetic biology community also support an 
ethos of open innovation, and have concerns about the adverse effects 
intellectual property rights (primarily patents) could have on the 
development of their field.
4
 
Numerous standards have been proposed in synthetic biology, 
including those relevant to structure, function, description, 
measurement, data, information exchange, software, biosafety and 
biosecurity,
5
 and even law.  Adoption of most of these proposed 
 
 1. Edward Tatum, Nobel Lecture: A Case History in Biological Research, 
NOBELPRIZE.ORG. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1958/tatum-
lecture.html (last visited Nov. 9, 2013). 
 2. Tal Danino, et al., A Synchronized Quorum of Genetic Clocks, 463 NATURE 326 
(2010) (explaining how “‘[s]ynthetic biology’ can be broadly parsed into efforts aimed at the 
large-scale synthesis of DNA and the forward engineering of genetic circuits from known 
biological components”). 
 3. See, e.g., Drew Endy, Foundations for Engineering Biology, 438 NATURE 449, 449 
(2005). 
 4. See, e.g., Sibylle Gaisser & Thomas Reiss, Shaping the Science-Industry-Policy 
Interface in Synthetic Biology, 3 SYST. SYNTH. BIOL. 109, 112 (2009) (stating that "[t]he unclear 
patent situation creates a feeling of uneasiness among scientists"). 
 5. The term “biosafety” refers to issues related to the safety of humans, nonhuman 
organisms, or ecosystems from the potential for accidental or uncontrolled release of 
experimental organisms, standards for which are presented in the NIH Guidelines for Res. 
Involving Recombinant or Synthetic Nucleic Acid Molecules (November 2013), 
http://oba.od.nih.gov/oba/rac/Guidelines/NIH_Guidelines.pdf.  There are also amendments that 
modify the scope of the NIH guidelines (announced September 5, 2012).  See Dep’t of Health & 
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standards has thus far been quite modest.
6
  A notable exception 
involves biosecurity, where standards for screening DNA synthesis 
orders have been widely adopted.
7
  The simultaneous wealth of 
proposed standards and dearth of adopted standards may be due, in 
part, to the relative youth of the synthetic biology field and its rapid 
technical evolution.  For example, early enthusiasm for structural and 
assembly standards may become less urgent as the technology of 
large-molecule DNA synthesis improves.  Nevertheless, interest in 
standards setting remains a prominent feature of the synthetic biology 
field. 
A number of organizations have articulated standards setting in 
synthetic biology as an important goal.  These include the BioBricks 
Foundation (BBF),
8
 the International Genetically Engineered Machine 
(iGEM) Foundation,
9
 the Synthetic Biology Engineering Research 
Center (SynBERC),
10
 BIOFAB: International Open Facility 
Advancing Biotechnology (BIOFAB),
11
 the Synthetic Biology Open 
Language (SBOL) Team,
12
 the Synthetic Biology Standards Network 
(SynBioStandards Network),
13
 the International Association of 
Synthetic Biology (IASB),
14
 the International Consortium for 
Polynucleotide Synthesis (ICPS),
15
 and the Flowers Consortium.
16
  
 
Human Servs., National Institutes of Health (Sept. 5, 2012), 
http://oba.od.nih.gov/oba/rac/fractions/77_FR_54584.pdf.  This report will focus on standards 
for “biosecurity” which encompasses safety issues that arise from the potential for intentional or 
malevolent release of harmful organisms, whether natural or experimental. 
 6. Linda J. Kahl & Drew Endy, A Survey of Enabling Technologies in Synthetic Biology, 
J. BIOL. ENG. (May 10, 2013), http://www.jbioleng.org/content/7/1/13. 
 7. See, e.g., Markus Schmidt & Gregor Giersch, DNA Synthesis and Security, in DNA 
MICROARRAYS, SYNTHESIS AND SYNTHETIC DNA 285, 297 (Marissa J. Campbell ed., 2011), 
available at http://www.markusschmidt.eu/pdf/NOVA-Schmidt-print.pdf (“Despite the co-
existence of several guidelines for DNA synthesis (companies), the overall field can be regarded 
as being under good control from a security point of view.”). 
 8. See BIOBRICKS FOUNDATION, http://biobricks.org (last visited Jan. 27, 2014). 
 9. See IGEM, http://igem.org (last visited Jan. 27, 2014). 
 10. See THE SYNTHETIC BIOLOGY ENGINEERING RESOURCE CENTER, 
http://www.synberc.org (last visited Feb. 1, 2014). 
 11. See BIOFAB INTERNATIONAL OPEN FACILITY ADVANCING BIOTECHNOLOGY, 
http://biofab.org (last visited Feb. 1, 2014). 
 12. See SYNTHETIC BIOLOGY OPEN LANGUAGE, http://www.sbolstandard.org (last visited 
Feb. 1, 2014). 
 13. See SYNTHETIC BIOLOGY STANDARDS NETWORK, http://www.synbiostandards.co.uk 
(last visited Feb. 1, 2014). 
 14. See INTERNATIONAL ASSOCIATION OF SYNTHETIC BIOLOGY, http://www.ia-
sb.eu/go/synthetic-biology/ (last visited Feb. 1, 2014). 
 15. Hans Bügl et al., DNA synthesis and biological security, 25 NAT. BIOTECHNOL. 627 
(2007) (articulates the recommendations of the International Consortium for Polynucleotide 
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Another prominent player has been the U.S. Department of Health 
and Human Services, which, in 2010, issued guidance on how to 
screen DNA synthesis orders that has been widely adopted by the 
DNA synthesis industry.
17
  At a more informal level, many scientists 
and a number of commercial firms have proposed standards relevant 
to various aspects of synthetic biology.
18
  In addition, there has been 
considerable interest in standards within the Do-It-Yourself Biology 
(DIYbio) movement, whose success in attracting wide participation 
may be influenced by the existence of standard components and 
protocols capable of use by amateur biologists.
19
 
Many in the synthetic biology community have voiced concerns 
that excessive intellectual property rights may have an adverse impact 
on the progress of the field.
20
  In theory, negative effects caused by 
patent rights covering commonly used components or methods in 
synthetic biology could be exacerbated if those patented components 
or methods were to be adopted as standards.  However, little evidence 
exists to suggest that this is currently the case.  In practice, the past 
few years have seen tremendous flux in how courts interpret the 
patent-eligibility of both methods, such as diagnostic tests, and 
components, such as isolated DNA molecules, essential to synthetic 
biology.  Notably, the Supreme Court invalidated claims to methods 
of combined diagnosis and therapy in Mayo v. Prometheus
21
 and to 
isolated genomic DNA in AMP v. Myriad.
22
   There is a substantial 
likelihood that the scope of subject matter in biotechnology currently 
considered patent-eligible will narrow, perhaps significantly.  
Copyright may be particularly suited to providing an alternative to 
patent protection for synthetic DNA, though its applicability to DNA 
is currently uncertain. 
 
Synthesis (ICPS) for an oversight framework for research involving commercial DNA 
synthesis). 
 16. See FLOWERS CONSORTIUM, http://www.synbiuk.org (last visited Feb. 1, 2014). 
 17. Dep’t of Health and Human Servs., Screening Framework Guidance for Providers of 
Synthetic Double-Stranded DNA, 75 Fed. Reg. 62,820 (Oct. 13, 2010). 
 18. See, e.g., Adam Arkin, Setting the Standard in Synthetic Biology, 26 NAT. 
BIOTECHNOL. 771 (2008). 
 19. See, e.g., Todd Kuiken, DIYbio: Low Risk, High Potential, THE SCIENTIST (Mar. 1, 
2013), http://www.the-scientist.com/?articles.view/articleNo/34443/title/DIYbio--Low-Risk--
High-Potential. 
 20. See, e.g., Arti Rai & James Boyle, Synthetic Biology: Caught between Property 
Rights, the Public Domain, and the Commons, 5 PLOS BIOL. (March 13, 2007), 
http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.0050058. 
 21. Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289 (2012). 
 22. Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107 (2013). 
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This report resulted from a study of standards setting efforts by 
the institutions, firms, governments, and individuals within the field 
of synthetic biology.  It is based on a review of the relevant published 
literature and web-based information.  Section I provides a brief 
introduction to the field of synthetic biology.  Section II surveys 
standards, standards setting efforts, and related institutions.  Section 
III discusses intellectual property issues and rights relevant to 
synthetic biology and standards setting.  Section IV summarizes the 
findings of the report. 
I. OVERVIEW OF SYNTHETIC BIOLOGY 
In aspiring to become a true engineering discipline, the field of 
synthetic biology differs markedly from most other fields within 
biology.  During the early days of synthetic biology’s emergence, 
Drew Endy suggested standardization, decoupling, and abstraction as 
important principles for the engineering of biology.
23
 He described 
standardization as “the definition, description and characterization of 
the basic biological parts, as well as standard conditions that support 
the use of parts in combination and overall system operation.”24  
However, he has also acknowledged the possibility that biology may 
be too complex to yield easily to engineering approaches. 
Biology differs substantially from the physical and computer 
sciences.  Biological systems tend to be more complex and less 
predictable, making both understanding and (re)designing them 
challenging.  There may be theoretical limits on the ability to describe 
and reconstruct any but the simplest biological systems, with little 
prospect of overcoming these limits in the near future.
25
  In addition, 
practical limitations include the difficulty in defining and measuring 
the functions of standard biological parts—such as BioBricks, the 
unpredictability of genetic circuitry (necessitating exactly the kinds of 
trial and error experimentation synthetic biology is meant to avoid), 
the challenges posed by biological complexity, the mutual 
incompatibility of many standard parts, and the tendency for 
variability within biological units to render biological systems prone 
to failure.
26
  For example, synthetic gene networks tend to be resistant 
to precisely programmed behavior due to cell-by-cell variability and 
 
 23. Endy, supra note 3, at 450. 
 24. Id. 
 25. Christof Koch, Modular Biology Complexity, 337 SCIENCE 531 (2012). 
 26. Roberta Kwok, Five Hard Truths for Synthetic Biology, 463 NATURE 288 (2010). 
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intrinsic stochasticity.
27
  Jesse Stricker urged “caution must be 
exercised when making simplifying assumptions in the design of 
engineered gene circuits.”28 
The applied nature of synthetic biology has resulted in a small 
industry that is rapidly evolving.
29
  Commercial synthetic biology 
represents a modest fraction of the biotechnology industry, and firms 
have experienced mixed success.  Among the most prominent are 
DNA 2.0, Inc.,
30
 and Blue Heron Biotech, LLC,
31
 providers of 
synthetic genes; Amyris, Inc.,
32
 which engineered a pathway for 
synthesizing a precursor to the anti-malarial artemisinin; LS9, Inc. 
(recently acquired by Renewable Energy Group, Inc.)
33
 and Qteros, 
Inc.,
34
 developers of biofuels; Ginkgo BioWorks,
35
 a biological 
engineering company; and Synthetic Genomics, Inc., a developer of 
synthetic genomics technologies, such as Gibson Assembly,
36
 and 
owner of a substantial patent portfolio.
37
  Codon Devices, Inc., an 
early DNA synthesis firm, went bankrupt in 2009,
38
 although a new 
venture, Gen9, Inc., has since emerged and is developing technology 
to support synthesis and assembly of larger DNA constructs.
39
 
A prevalent theme within the synthetic biology community is the 
value of an open science ethos.
40
  This ethos often promotes open 
 
 27. Danino et al., supra note 2. 
 28. Jesse Stricker et al., A Fast, Robust and Tunable Synthetic Gene Oscillator, 456 
NATURE 516 (2008). 
 29. SYNBIOBETA, http://synbiobeta.com (last visited Jan. 30, 2014). 
 30. DNA 2.0, INC., https://www.dna20.com (last visited Jan. 30, 2014). 
 31. BLUE HERON BIOTECH, LLC, http://www.blueheronbio.com (last visited Jan. 30, 
2014). 
 32. AMYRIS, INC., http://www.amyris.com (last visited Jan. 30, 2014). 
 33. Press Release, Renewable Energy Group, Inc., Renewable Energy Group Enters 
Indus. Biotech with Acquisition of LS9 (Jan 22, 2014), available at 
http://www.regi.com/news/2014/01/22/renewable-energy-group-enters-industrial-biotech-
acquisition-ls9. 
 34. QTEROS, INC., http://www.qteros.com (last visited Jan. 30, 2014). 
 35. GINGKO BIOWORKS, http://ginkgobioworks.com (last visited Jan. 30, 2014). 
 36. SGI-DNA, http://www.sgidna.com/products.php. (last visited Jan. 27, 2014). 
 37. Among the patent applications owned by Synthetic Genomics, Inc. are U.S. Patent 
No. 20070122826 (filed Oct. 12, 2006) (“Minimal Bacterial Genome”); U.S. Patent No. 
20070264688 (filed Dec. 6, 2006) (“Synthetic Genomes”); and U.S. Patent No. 20110053273 
(filed May 19, 2010) (“Methods for Cloning and Manipulating Genomes”). 
 38. Todd Wallack, Codon Devices Closing as Financing Dwindles, THE BOSTON GLOBE 
(April 3, 2009), 
http://www.boston.com/business/healthcare/articles/2009/04/03/codon_devices_closing_as_fina
ncing_dwindles/. 
 39. GEN 9, INC., http://www.gen9bio.com (last visited Jan. 30, 2014). 
 40. Stephen M. Maurer, Before It’s Too Late – Why Synthetic Biologists Need an Open-
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sharing of information among biologists as well as considerable 
attention to the effects that patent rights may have on the evolution of 
the field.  For example, the BioBricks Foundation and the iGEM 
Foundation have tended to promote open sharing of both parts and 
information, while trying to develop methods for detecting and 
avoiding patents that might interfere with such openness.
41
  However, 
it appears highly likely that universities and firms have already 
acquired considerable patent rights in various aspects of synthetic 
biology—patent rights that could interfere with open science 
practices.
42
  Thus far, there is little evidence that patents covering 
aspects of synthetic biology have, in fact, been used in this manner. 
One notable feature of standards setting and intellectual property 
in synthetic biology is the recurring participation of a relatively small 
group of academic scientists, a substantial minority of them with 
formal training as engineers, who have serially founded and led many 
of the institutions noted above. 
II. STANDARDS AND STANDARDS-SETTING IN SYNTHETIC BIOLOGY 
A. Technical Standards 
Within the synthetic biology community, researchers are actively 
working to develop technical standards for genetically encoded 
functions that will enable the efficient production, distribution and re-
use of biological parts.  To date, technical standards relevant to 
synthetic biology applications are being developed in at least four 
broad categories: physical composition, functional composition, units 
of measurement, and data exchange.
43
 
Physical composition standards support the physical assembly of 
 
Parts Collaboration – and How to Build One, 10 EMBO REPORTS 806 (2009); Joachim Henckel 
& Stephen M. Maurer, The Economics of Synthetic Biology, MOL. SYST. BIOL., June 5, 2007, 
available at http://www.nature.com/msb/journal/v3/n1/full/msb4100161.html; David Cohn, 
Open-Source Biology Evolves, WIRED (Jan. 17, 2005), 
http://www.wired.com/medtech/health/news/2005/01/66289?currentPage=all. 
 41. An example of this is the development by the BioBricks Foundation of the BioBrick 
User and Contributor Agreements, together, the BioBrick Public Agreement (BPA), The 
BioBrick Public Agreement (BPA), BIOBRICKS FOUNDATION, https://biobricks.org/bpa/ (last 
visited Feb. 18, 2014), and the requirement that all participants in the iGEM competition 
contribute the parts they make to the iGEM Registry of Standard Biological Parts.  See What 
about these standard parts?, IGEM, http://igem.org/About (last visited March 4, 2014). 
 42. Sapna Kumar & Arti Rai, Synthetic Biology: The Intellectual Property Puzzle, 85 
TEX. L. REV. 1745 (2007); Davy van Doren, Stefan Koenigstein, & Thomas Reiss, The 
Development of Synthetic Biology: A Patent Analysis, 7 SYST. SYNTH. BIOL. 209-20 (2013). 
 43. See Technical Standards Framework, BIOBRICKS FOUNDATION, 
http://biobricks.org/programs/technical-standards-framework (last visited Jan. 27, 2014). 
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individual biological parts into multi-component systems.  One of the 
earliest examples of a physical composition standard in synthetic 
biology is the original BioBrick assembly standard (BBF RFC 10), 
which uses iterative restriction enzyme digestion and ligation 
reactions to assemble small biological parts into larger composite 
parts.
44
  This standard initially served as the primary means for 
physical assembly of biological parts by teams participating in the 
iGEM competition,
45
 and thousands of parts in the iGEM Registry of 
Standard Biological Parts
46
 have been constructed following this 
standard. As technology has advanced, the BioBrick assembly 
standard has undergone a number of refinements and other physical 
composition standards that provide additional flexibility for the 
physical assembly of biological parts have been introduced.
47
 
Although the BioBrick assembly standard and other methods that 
build upon this standard have proven useful to many groups,
48
 it is 
 
 44. Thomas Knight, Idempotent Vector Design for Standard Assembly of BioBricks (MIT 
Artificial Intelligence Lab. & MIT Synthetic Biology Working Grp., 2003), available at 
http://hdl.handle.net/1721.1/21168. 
 45. IGEM, supra note 9. 
 46. See Registry of Standard Biological Parts, IGEM, http://parts.igem.org/Main_Page 
(last visited March 4, 2014). 
 47. See, e.g., Ira Phillips & Pamela Silver, BBF RFC 23: A New BioBrick Assembly 
Strategy Designed for Facile Protein Engineering, DSPACE@MIT (Apr. 18, 2006), 
http://hdl.handle.net/1721.1/32535; Thomas Knight, BBF RFC 2: Draft Standard for BioBrick 
BB-2 Biological Parts, DSPACE@MIT (Nov. 19, 2008), http://hdl.handle.net/1721.1/45139; 
Reshma P. Shetty, Drew Endy & Thomas F. Knight, Engineering BioBrick Vectors from 
BioBrick Parts, J. BIOL. ENG. (April 14, 2008), http://www.jbioleng.org/content/2/1/5; Michael 
Ellison et al., BBF RFC 47: BioBytes Assembly Standard, DSPACE@MIT (Oct. 29, 2009), 
http://hdl.handle.net/1721.1/49518; Katja Arndt et al., BBF RFC 25: Fusion Protein (Freiburg) 
BioBrick Assembly Standard, DSPACE@MIT (Apr. 18, 2009), 
http://hdl.handle.net/1721.1/45140; Sergio G. Peisajovich et al., BBF RFC 28: A Method for 
Combinatorial Multi-Part Assembly Based on the Type IIs Restriction Enzyme AarI, 
DSPACE@MIT (Sept. 16, 2009), http://hdl.handle.net/1721.1/46721; J. Christopher Anderson et 
al., BglBricks: A Flexible Standard for Biological Part Assembly, J. BIOL. ENG. (Jan. 20, 2010), 
http://www.jbioleng.org/content/4/1/1; Sean C. Sleight et al., In-Fusion BioBrick Assembly and 
Re-engineering, 38 NUCLEIC ACIDS RES. 2624 (2010); Reshma Shetty et al., Assembly of 
BioBrick Standard Biological Parts Using Three Antibiotic Assembly, 498 METHODS ENZYMOL. 
311 (2011). 
 48. See, e.g., Karmella A. Haynes et al., Engineering Bacteria to Solve the Burnt Pancake 
Problem, J. BIOL. ENG. (May 20, 2008), http://www.jbioleng.org/content/2/1/8; Bruno Afonso et 
al., A Synthetic Circuit for Selectively Arresting Daughter Cells to Create Aging Populations, 1 
NUCLEIC ACIDS RES. 2727 (2010); Raik Grunberg et al., Building Blocks for Protein Interaction 
Devices, 38 NUCLEIC ACIDS RES. 2645 (2010); Hsin-Ho Huang et al., Design and 
Characterization of Molecular Tools for a Synthetic Biology Approach towards Developing 
Cyanobacterial Biotechnology, 38 NUCLEIC ACIDS RES. 2577 (2010); Marco Constante et al., A 
Biobrick Library for Cloning Custom Eukaryotic Plasmids, PLOS ONE (August 25, 2011), 
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0023685; Elisabeth 
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now possible to assemble biological parts without the use of 
restriction enzymes.  Methods such as Gibson Assembly,
49
 Seamless 
Ligation Cloning Extract (SLiCE),
50
 and others,
51
 enable the seamless 
construction of large DNA molecules and do not impose sequence 
constraints on the design of biological parts.  Yet another approach, 
often used in conjunction with other physical assembly methods, is de 
novo DNA synthesis.
52
  With continued improvements in the capacity 
to synthesize DNA constructs at ever more affordable prices, de novo 
synthesis of multicomponent devices and systems may become 
feasible.
53
  So far, no single approach has become a de facto standard 
for the physical assembly of biological parts and physical 
composition standards will likely continue to evolve.
54
 
Functional composition standards support the ability of 
assembled biological parts to function in a predictable manner.  As an 
example, the Expression Operating Unit (EOU) is a genetic layout 
architecture that enables forward engineering at the genome scale by 
ensuring that independent expression elements perform reliably 
across different genetic contexts.
55
  Other tools that help rationally 
 
Linton et al., Translocation of Green Fluorescent Protein by Comparative Analysis with 
Multiple Signal Peptides, 7 BIOTECHNOL. J. 667 (2012); Raul Cuero, J. Lilly & David S. 
McKay, Constructed Molecular Sensor to Enhance Metal Detection by Bacterial Ribosomal 
Switch-Ion Channel Protein Interaction, J. BIOTECHNOL., March 2012, at 1; Liping Du et al., 
Multigene Expression In Vivo: Supremacy of Large Versus Small Terminators for T7 RNA 
Polymerase, 109 BIOTECHNOL. & BIOENG. 1043 (2012). 
 49. Daniel G. Gibson et al., Enzymatic Assembly of DNA Molecules up to Several 
Hundred Kilobases, 6 NAT. METHODS 343 (2009). 
 50. Yongwei Zhang et al., SLiCE: A Novel Bacterial Cell Extract-Based DNA Cloning 
Method, 40 NUCLEIC ACIDS RES. e55 (2012). 
 51. See, e.g., Baogong Zhu et al., In-Fusion Assembly: Seamless Engineering of 
Multidomain Fusion Proteins, Modular Vectors, and Mutations, 43 BIOTECHNIQUES 354 
(2007); Carola Engler et al., A One Pot, One Step, Precision Cloning Method with High 
Throughput Capability, PLOS ONE (Nov. 5, 2008), 
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0003647; Jiayuan 
Quan & Jingdong Tian, Circular Polymerase Extension Cloning of Complex Gene Libraries and 
Pathways, PLOS ONE (July 30, 2009), 
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0006441; Patrick M. 
Boyle et al., A BioBrick Compatible Strategy for Genetic Modification of Plants, 6 J. BIOL. ENG. 
8 (2012); Arjen J. Jakobi & Eric G. Huizinga, A Rapid Cloning Method Employing Orthogonal 
End Protection, PLOS ONE (June 7, 2012), 
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0037617. 
 52. Peter A. Carr & George M. Church, Genome Engineering, 27 NAT. BIOTECHNOL. 
1151 (2009). 
 53. Robert Carlson, The Changing Economics of DNA Synthesis, 27 NAT. BIOTECHNOL. 
1091 (2009). 
 54. Kahl, supra note 6. 
 55. Vivek K. Mutalik et al., Precise and Reliable Gene Expression via Standard 
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predict the modulators of gene expression, such as the ribosome 
binding site (RBS) calculator
56
 and calculators for promoter 
strength,
57
 also are useful as an approach for the functional 
composition of assembled biological parts and devices. 
Standards for units of measurement enable independent 
researchers to make measurements of genetically encoded functions 
that account for variation introduced by differences in experimental 
conditions and instruments.  They are also sharable across multiple 
laboratories.  As an example, the Relative Promoter Unit (RPU) is a 
standard unit for reporting promoter activity, where RPU is defined as 
a ratio of the absolute activity of a sample promoter relative to the 
absolute activity of a standard reference promoter.
58
  Because the 
RPU is a relative measure, as opposed to an absolute measure, it is 
not tied to a single measurement procedure and so different 
laboratories are free to select whatever procedures they find most 
convenient and suitable.  The concept of the RPU was initially 
demonstrated using promoters in E. coli, and has since been extended 
for promoter characterization in mammalian cells.
59
  Another 
measurement standard that has been proposed is Polymerase Per 
Second, or PoPS.
60
  Conceptually similar to the current in a wire that 
connects two electronic components, PoPS represents the flow of 
RNA polymerase molecules along the DNA.
61
  By defining PoPS as 
the number of times that an RNA polymerase molecule passes a 
specific point on DNA per unit time, PoPs provides a measure of 
transcription rate and can be used to characterize molecular devices 
such as genetic circuits.
62
 
 
Transcription and Translation Initiation Elements, 10 NAT. METHODS 354 (2013). 
 56. Howard M. Salis, Ethan A. Mirsky & Christopher A. Voigt, Automated Design of 
Synthetic Ribosome Binding Sites to Control Protein Expression, 27 NAT. BIOTECHNOL. 946 
(2009). 
 57. Virgil A. Rhodius, Vivek K. Mutalik & Carol A. Gross, Predicting the strength of 
UP-elements and full-length E. coli E promoters, 40 NUCLEIC ACIDS RES. 2907 (2012). 
 58. Jason R. Kelly et al., Measuring the Activity of BioBrick Promoters Using an In Vivo 
Reference Standard, J. BIOL. ENG. (March 20, 2009), http://www.jbioleng.org/content/3/1/4. 
 59. Lars Velten et al., Units for Promoter Measurement in Mammalian Cells, 
DSPACE@MIT (Oct. 21, 2009), http://hdl.handle.net/1721.1/49501. 
 60. For a colorful and amusing description of PoPS, the reader is referred to a comic book 
authored by Drew Endy and Isadora Deese and illustrated by Chuck Wadey.  Drew Endy & 
Isadora Deese, Adventures in Synthetic Biology, MIT SYNTHETIC BIOLOGY WORKING GROUP, 
http://mit.edu/endy/www/scraps/comic/AiSB.vol1.pdf (last visited Feb. 19, 2014). 
 61. Id. 
 62. Prasanna Amur Varadarajan & Domitilla Del Vecchio, Design and Characterization 
of a Three-Terminal Transcriptional Device through Polymerase Per Second, IEEE TRANS. 
NANOBIOSCIENCE, Sept. 2009, at 281 (describing PoPS as analogous to an electrical current, and 
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Data exchange standards enable researchers to query and retrieve 
information needed to more efficiently design new biological parts, 
devices, and systems for synthetic biology applications.  As an 
example, Synthetic Biology Open Language (SBOL) is a software 
standard for the electronic exchange of specifications and descriptions 
of genetic parts, devices, modules, systems, and engineered 
genomes.
63
  The SBOL semantic was used to create the Standard 
Biological Parts Knowledgebase (SBPkb), which has been populated 
with the 13,000 parts from the iGEM Registry of Standard Biological 
Parts and is anticipated to serve as the first node in a framework for a 
semantic web of distributed knowledge in synthetic biology.
64
  In 
addition, SBOL visual (SBOLv) has been proposed as a graphical 
notation standard for the visual display of information about the 
physical composition of basic and composite parts used in the 
development of biological devices.
65
  Additional standardization 
efforts for data exchange have focused on the development of 
datasheets that describe the formal specifications for basic and 
composite parts, and example datasheets summarizing the relevant 
physical characteristics and performance features of biological parts 
have been proposed.
66
 
B. Technical Standards-Setting Organizations 
As in other engineering disciplines, standards are best developed 
by consensus and this is no less true in synthetic biology (Table 1).
67
  
An organizational framework to help define, evaluate, and propose 
technical standards in synthetic biology has been created by the 
BioBricks Foundation.
68
  This framework, known as the BioBrick 
Request for Comments (RFC) process, has been instrumental in 
 
characterizing a three-terminal transcriptional device using PoPS as input and output). 
 63. SBOL Team, SYNTHETIC BIOLOGY OPEN LANGUAGE, 
http://www.sbolstandard.org./community (last visited Jan 27, 2014). 
 64. Michal Galdzicki et al., Standard Biological Parts Knowledgebase, PLOS ONE (Feb. 
24, 2011), http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0017005. 
 65. Jacqueline Quinn et al., BBF RFC 93: Synthetic Biology Open Language Visual 
(SBOLv) version 1.0.0, DSPACE@MIT (March 31, 2013), http://hdl.handle.net/1721.1/78249. 
 66. See, e.g., Barry Canton, Anna Labno & Drew Endy, Refinement and Standardization 
of Synthetic Biological Parts and Devices, 26 NAT. BIOTECHNOL. 787 (2008); Taek S. Lee et al., 
BglBrick Vectors and Datasheets: A Synthetic Biology Platform for Gene Expression, J. BIOL. 
ENG. (Sept. 20, 2011), http://www.jbioleng.org/content/5/1/12; Kenneth Evan Thompson et al., 
SYNZIP Protein Interaction Toolbox: In Vitro and In Vivo Specifications of Heterospecific 
Coiled-Coil Interactions Domains, 1 ACS SYNTH. BIO. 118 (2012). 
 67. See infra Table 1. 
 68. BIOBRICKS FOUNDATION, supra note 8. 
TORRANCE & KAHL 4/2/2014  11:00 PM 
2014] BRINGING STANDARDS TO LIFE 211 
facilitating discussion and coordinating the efforts of multiple 
researchers in technical standards development.
69
  Initiated in 2008, 
the BioBrick RFC process was inspired by and modeled upon the 
RFC process of the Internet Engineering Task Force, and currently 
contains over 100 technical documents.
70
  These documents may 
propose a technical standard, describe best practices or protocols, or 
simply provide information.
71
  As new BioBrick RFCs are added, 
they may comment upon, extend, or replace earlier RFCs.  In this way 
the BioBrick RFC process serves as a convenient, useful vehicle for 
documenting and distributing information so that a general consensus 
may eventually emerge and lead to the widespread adoption of 
technical standards. 
Technical standards development efforts also have been initiated 
by the BIOFAB.  The concept for creating a BIOFAB was initially 
proposed in 2006.
72
  Drawing upon analogies to the semiconductor 
industry, the idea was put forth that a fabrication platform using 
standardized methods and libraries of compatible biological parts 
could empower engineers to design and build sophisticated biological 
devices and systems with greater efficiency and speed than is possible 
using conventional molecular biology approaches.
73
  Towards that 
end, the world’s first biological design-build facility was founded in 
2009 and located in Emeryville, California.
74
  Funded by a 2-year 
grant from the National Science Foundation, the Emeryville BIOFAB 
was operated in partnership with Lawrence Berkeley National 
Laboratory, the BioBricks Foundation, and SynBERC.
75
  There, the 
BIOFAB team developed a mathematical framework for quantifying 
the intrinsic activities of genetic elements and designed a genetic 
 
 69. See RFC Process, BIOBRICKS FOUNDATION, http://biobricks.org/programs/technical-
standards-framework/ (last visited Feb. 1, 2014). 
 70. A listing of assigned RFC numbers and documents may be found at The BioBricks 
Foundation: RFC, OPENWETWARE, 
http://openwetware.org/wiki/The_BioBricks_Foundation:RFC#BBF_RFC_0:_Instructions_to_B
BF_RFC_Authors (last visited Jan. 30, 2014). 
 71. Daniel Tarjan et al., BBF RFC 0: Instructions to BBF RFC Authors, DSPACE@MIT 
(Nov. 10, 2008), http://hdl.handle.net/1721.1/44960. 
 72. David Baker et al., Engineering Life: Building a FAB for Biology, SCI. AM., June 
2006, at 44. 
 73. BIOFAB, supra note 11. 
 74. Id. 
 75. The Emeryville BIOFAB facility maintains a neutral posture with respect to 
intellectual property rights so that the facility will be able to support partnerships with academic 
and commercial entities, some of whom might work with the BIOFAB in developing both 
improved open access and propriety parts. See SynBERC Parts on Demand, BIOFAB, 
http://biofab.org/projects (last visited Jan. 30, 2014). 
TORRANCE & KAHL   4/2/2014  11:00 PM 
212 SANTA CLARA HIGH TECH. L.J. [Vol. 30 
layout architecture to help eliminate the functional uncertainty that 
arises from the reuse of transcription and translation control elements 
with sequence-distinct protein coding regions.
76
  A second BIOFAB, 
founded at Stanford University in 2012 and supported by the 
BioBricks Foundation, aims to map the central dogma of yeast and 
contribute standardized biological parts to the public domain.
77
  The 
BioBricks Foundation aspires to build a network of BIOFABs around 
the world to create synergy and foster the development of 
community-driven technical standards and production of standardized 
biological parts.
78
 
Additional efforts in technical standards development have been 
initiated by the SBOL Team.
79
  Development of the SBOL standard 
began in 2008 (then in a format known as Provisional BioBrick 
Language, or PoBoL),
80
 and this community-based effort has 
consistently grown in size and sophistication as the SBOL standard 
continues to evolve to meet the needs of synthetic biology researchers 
and engineers.
81
  The core data model for the SBOL standard supports 
organization of the essential information for synthetic DNA 
sequences,
82
 and extensions to the core data model support 
visualization of biological designs and the communication of 
additional information.
83
  The SBOL standard underlies the SBPkb, 
which is a semantic web resource that allows researchers to query and 
retrieve information about biological parts from the iGEM Registry of 
 
 76. Vivek K. Mutalik et al., Quantitative Estimation of Activity and Quality for 
Collections of Functional Genetic Elements, 10 NAT. METHODS 347 (2013); Mutalik, supra note 
55. 
 77. See Stanford BIOFAB, BIOBRICKS FOUNDATION, 
http://biobricks.org/programs/technical-program (last visited Jan. 30, 2014). 
 78. See Global BIOFAB Network, BIOBRICKS FOUNDATION, 
http://biobricks.org/programs/technical-program (last visited Jan. 30, 2014). 
 79. SBOL is an open-specification, open-source project in which a diverse community of 
individuals from academia, industry and public benefit organizations work collaboratively to 
create data exchange standards for describing and communicating information about genetic 
parts, devices, modules, and systems.  See SYNTHETIC BIOLOGY OPEN LANGUAGE, supra note 
12. 
 80. Michal Galdzicki et al., BBF RFC 31: Provisional BioBrick Language (PoBoL), 
DSPACE@MIT (May 15, 2009), http://hdl.handle.net/1721.1/45537. 
 81. Michael Galdzicki et al., BBF RFC 87: Synthetic Biology Open Language (SBOL) 
Version 1.1.0., DSPACE@MIT (Oct. 11, 2012), http://hdl.handle.net/1721.1/73909. 
 82. Jean Peccoud et al., Essential Information for Synthetic DNA Sequences, 29 NAT. 
BIOTECHNOL. 22 (2011). 
 83. Quinn, supra note 65; Jeffrey Johnson et al., BBF RFC 68: Standard for the 
Electronic Distribution of SBOLv Diagrams, DSPACE@MIT (Dec. 05, 2010), 
http://hdl.handle.net/1721.1/60086. 
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Standard Biological Parts.
84
  Similarly, the Joint BioEnergy Institute 
Inventory of Composable Elements (JBEI-ICE), a public registry of 
biological parts developed by the Joint BioEnergy Institute, supports 
the SBOL data exchange standard.
85
  In addition, several SBOL-
compliant software tools have been developed for synthetic biology 
(Table 2).
86
 
Synthetic biology standards also have been addressed by the 
Synthetic Biology Standards Network (SynBioStandards Network), 
an interdisciplinary network for UK academics working in synthetic 
biology.
87
  Though it does not consider itself to be a standards setting 
organization, the SynBioStandards Network aims to develop a 
common language among researchers from the fields of engineering, 
biological sciences, computer science, and the social sciences and to 
develop approaches, tools, and protocols that may become gold 
standard and adopted by synthetic biology researchers worldwide.
88
 
Standards setting efforts have been prominent throughout the 
development of synthetic biology, at least in part due to participation 
in the field by engineers, computer scientists, and others who are 
familiar and comfortable with technical standards.
89
  One worry has 
been that the imposition of standards too early in the evolution of 
synthetic biology might canalize the trajectory of the field, 
discouraging alternative directions and impeding innovation.  
However, little evidence exists to support this worry.  None of the 
technical standards proposed thus far have been made mandatory for 
the field as a whole, and no governance body with the authority to 
impose mandatory technical standards for synthetic biology has yet 
been established.  In fact, even the most promising technical standards 
 
 84. Galdzicki, supra note 64. 
 85. Timothy S. Ham et al., Design, Implementation and Practice of JBEI-ICE: An Open 
Source Biological Part Registry Platform and Tools, 40 NUCLEIC ACIDS RES. e141, (2012), 
available at http://nar.oxfordjournals.org/content/40/18/e141.full.pdf+html. 
 86. A vast array of software tools have been developed for synthetic biology, some of 
which are SBOL-compliant. See infra Table 2.  For recent review see Adrian L. Slusarczyk, 
Allen Lin & Ron Weiss, Foundations for the Design and Implementation of Synthetic Genetic 
Circuits, 13 NATURE 406 (2012). 
 87. The SynBioStandards Network was funded for three years beginning in June 2008 by 
the Arts & Humanities Research Council, the Biotechnology and Biological Sciences Research 
Council, Economic & Social Research Council, and the Engineering and Physical Sciences 
Research Council.  See About the SynBioStandards Network, SYNTHETIC BIOLOGY STANDARDS 
NETWORK, http://www.synbiostandards.co.uk/about.php (last visited Feb. 19, 2014). 
 88. Id. 
 89. Adam Arkin, Setting the Standard in Synthetic Biology, 26 NAT. BIOTECHNOL. 771 
(2008); Arti Rai, Unstandard Standarization: The Case of Biology, 53 COMMS. ACM 37 (2010). 
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seem to have served in a transitory capacity given the speed at which 
scientific and technical advances in synthetic biology occur.  For 
example, a number of proposed technical standards pertaining to the 
physical assembly of DNA fragments into larger DNA molecules are 
being displaced by distinctly different methods, such as Gibson 
Assembly and de novo DNA synthesis.
90
  The iterative and 
progressive nature of technical standards development has been 
embraced by the synthetic biology research community, as evidenced 
by the BioBricks Foundation’s RFC process, which provides an 
avenue for the improvement, and even outright replacement, of earlier 
proposed technical standards.
91
  Only in the realm of biosecurity has 
any standard risen to the level of wide acceptance within the synthetic 
biology community, and there, the primary proponent of the standard 
adopted was the U.S. federal government.  At the present time, 
standards setting efforts do not appear to have affected the 
development of synthetic biology adversely. 
 
Table 1. Standard Setting Organizations and Intellectual 
Property Policies in Synthetic Biology 
 
 90. Kahl, supra note 6. 
 91. RFC Process, supra note 69. 
Standards 
Setting 
Organization 
Example Technical 
Standards 
Intellectual Property 
Policy 
BioBrick 
Request For 
Comments 
(RFC) process 
 
Started: 2006 
Physical Composition: 
BioBrick standard 
(BBF RFC 10) 
BglBrick standard 
(BBF RFC 21) 
BioFusion standard 
(BBF RFC 23) 
Freiburg standard 
(BBF RFC 25) 
AarI cloning standard 
(BBF RFC 28) 
 
Units of Measure: 
Relative Promoter Unit (RPU) 
(BBF RFC 19) 
Relative Mammalian Promoter 
Unit (RMPU) 
(BBF RFC 41) 
 
The BioBricks 
Foundation advocates 
open technology 
platforms and technical 
standards, and 
encourages the donation 
of basic bioengineering 
knowledge into the 
public domain. 
 
The BioBricks 
Foundation does not 
hold any patents relating 
to technical standards 
and retains copyright to 
documents filed in the 
BioBrick RFC process. 
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Table 1. (continued) 
Standards 
Setting 
Organization 
Example Technical 
Standards 
Intellectual Property 
Policy 
Synthetic 
Biology Open 
Language 
(SBOL) Team 
 
Started: 2008 
Data Exchange: 
Synthetic Biology Open 
Language (SBOL) 
 
SBOL visual (SBOLv) 
 
SBOL is an open-
specification, open-
source, community-
based project. 
 
SBOL has been 
submitted to the 
BioBrick RFC process 
(BBF RFC 87) as a 
software standard for the 
electronic exchange of 
specifications and 
descriptions of genetic 
parts, devices, modules, 
systems, and engineered 
genomes. 
 
SBOLv has been 
submitted to the 
BioBrick RFC process 
(BBF RFC 93) as a 
graphical notation to 
support the description 
and specification of 
genetic designs. 
 
BIOFAB: 
International 
Open Facility 
Advancing 
Biotechnology 
(BIOFAB) 
 
Started: 2009 
Functional Composition: 
Expression Operating Unit 
(EOU) 
The Emeryville 
BIOFAB facility 
maintains a neutral 
posture with respect to 
intellectual property 
rights so that the facility 
will be able to support 
partnerships with 
academic and 
commercial entities. 
 
The Stanford BIOFAB 
aims to contribute parts 
to the public domain. 
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Table 2. SBOL-Compliant Software tools for Synthetic  
Biology 
 
Software Tool Description URL 
Bacillo 
Bricks
92
 
A catalogue of Bacillus subtilis 
virtual parts, provided in the 
form of mathematical models 
that can be composed to create 
genetic circuits. 
http://intbio.ncl.ac.uk/?
projects=standard-
virtual-parts 
Benchling 
Enables design, analysis and 
sharing of sequence data in the 
cloud. 
https://benchling.com 
Clotho
93
 
A data model-based tool and 
plugin environment that 
provides a data model for 
representing biological objects, 
a common API for 
manipulating these objects, and 
a common platform for 
developing Apps for designing 
synthetic biological systems. 
http://www.clothocad.o
rg 
DeviceEditor
94
 
A web-based visual design 
environment that mimics the 
intuitive visual whiteboard 
design process practiced in 
biological laboratories. 
http://j5.jbei.org 
Eugene
95
 
A human- and machine-
readable language for the 
specification of biological 
constructs. 
http://eugenecad.org 
Gene 
Designer
96
 
A software tool for designing 
DNA sequences de novo 
https://www.dna20.co
m/genedesigner 
 
  
 
 92. Goksel Misirli et al., BacillOndex: An Integrated Data Resource for Systems and 
Synthetic Biology, 10 J. INTEGRATED BIOINFORMATICS 224 (2013). 
 93. Bing Xia et al., Developer’s and User’s Guide to Clotho v2.0: A software platform 
for the creation of synthetic biological systems, 498 METH. ENZYMOL. 97 (2011). 
 94. Joanna Chen et al., DeviceEditor Visual Biological CAD Canvas, J. BIOL. ENG. (Feb. 
28, 2012), http://www.jbioleng.org/content/6/1/1. 
 95. Lesia Bilitchenko et al., Eugene – A Domain Specific Language for Specifying and 
Constraining Synthetic Biological Parts, Devices, and Systems, PLOS ONE (April 29, 2011), 
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0018882. 
 96. Alan Villalobos et al., Gene Designer: A Synthetic Biology Tool for Constructing 
Artificial DNA Segments, 7 BMC BIOINFORMATICS 285 (2006). 
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Table 2. (continued) 
Software Tool Description URL 
GenoCAD
97
 
A web-based application to 
design protein expression 
vectors, artificial gene network, 
and other genetic constructs 
http://genocad.org 
iBioSim
98
 
A project-based tool for the 
analysis of genetic 
circuits,metabolic networks, 
cell signaling pathways and 
other biological and chemical 
systems. 
http://www.async.ece.u
th.edu/iBioSim 
j5
99
 
A web-based software tool to 
automate the design of scar-less 
multipart DNA assembly 
protocols 
http://j5.jbei.org 
JBEI-ICE
100
 
An open source registry 
platform for managing 
information about biological 
parts. 
https://public-
registry.jbei.org 
MoSeC
101
 
A Java application for synthetic 
biology design that takes a 
model annotated with the DNA 
sequence information of genetic 
elements and converts it into a 
DNA sequence 
http://intbio.ncl.ac.uk/?
projects=mosec 
Proto 
BioCompiler
102
 
A platform for biological 
system designers to express 
desired system functions using 
a user-friendly, high-level, 
biologically-focused 
programming language. 
http://proto.bbn.com/co
mmons/ 
 
 97. Michael J. Czar, Yizhi Cai & Jean Peccoud, Writing DNA with GenoCAD, NUCLEIC 
ACIDS RES. (May 8, 2009), 
http://nar.oxfordjournals.org/content/37/suppl_2/W40.full?sid=d98aeb4e-4f35-4e8e-939d-
967a5ea028cc. 
 98. Chris J. Myers et al., iBioSim: A Tool for the Analysis and Design of Genetic Circuits, 
25 BIOINFORMATICS 2848 (2009). 
 99. Nathan J. Hillson, Rafael D. Rosengarten & Jay D. Keasling, j5 DNA Assembly 
Design Automation Software, 1 ACS SYNTHETIC BIOL. 14 (2012). 
 100. Ham, supra note 85. 
 101. Goksel Misirli et al., Model Annotation for Synthetic Biology: Automating Model to 
Nucleotide Sequence Conversion, 27 BIOINFORMATICS 973 (2011). 
 102. Jacob Beal, Ting Lu & Ron Weiss, Automatic Compilation from High-Level 
Biologically-Oriented Programming Language to Genetic Regulatory Networks, PLOS ONE 
(August  5, 2011), 
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0022490. 
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Table 2. (continued) 
Software Tool Description URL 
SBPkb
103
 
A semantic web resource that 
allows researchers to query and 
retrieve standard biological 
parts for research and use in 
synthetic biology. 
http://www.sbolstandar
d.org/sbol-in-
use/sbpkb 
TeselaGen 
A DNA design and assembly 
platform for Bio CAD/CAM 
systems 
https://www.teselagen.
com 
TinkerCell
104
 
An application for bringing 
together models, information 
and algorithms. 
http://www.tinkercell.c
om 
C. Biosecurity Standards Setting 
The development and implementation of standards for 
biosecurity has been of paramount importance in the field of synthetic 
biology.  As in other fields, research in synthetic biology may 
generate “dual use” findings that could be socially beneficial, such as 
new therapies, diagnostic methods, crops, and industrial processes, as 
well as harmful, such as new pathogens, toxins, or biological 
weapons.  Consequently, an early topic of discussion and planning 
among the synthetic biology community was how to minimize the 
risk of harmful applications of the technology.  As early as 2005, 
researchers, policy analysts and security experts in universities, 
research institutions, commercial firms, and government 
organizations have worked to develop biosecurity standards for 
synthetic biology. 
At the first Synthetic Biology conference (SB 1.0), in 2005, there 
was some discussion of biosecurity issues among the synthetic 
biology community.  Leading up to, and during, SB 2.0, in 2006, a 
discussion about biosecurity led to a formal proposal that synthetic 
biologists adopt a set of community biosecurity standards.
105
  With 
funding from the Carnegie Corporation Foundation and MacArthur 
Foundation, Stephen Maurer, Director of the Berkeley Information 
Technology and Homeland Security Project, led a project that 
 
 103. Galdzicki, supra note 64. 
 104. Deepak Chandran, Frank T. Bergmann & Herbert M. Sauro, TinkerCell: Modular 
CAD Tool for Synthetic Biology, J. BIOL. ENG. (Oct. 29, 2009), 
http://www.jbioleng.org/content/3/1/19. 
 105. Synthetic Biology: SB2.0/Biosecurity Resolutions, OPENWETWARE, 
http://openwetware.org/wiki/Synthetic_Biology:SB2.0/Biosecurity_resolutions (last visited Feb. 
1, 2014). 
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proposed six resolutions related to promoting an ethic of 
biosecurity.
106
  Another effort, funded by the Alfred P. Sloan 
Foundation, resulted in the development of a number of policy, 
technical, and other options to address the risks and benefits posed by 
dual-use nature of synthetic biology research.
107
 
In the wake of SB 2.0, several consortia of DNA synthesis 
companies developed their own standards for detecting orders for 
DNA sequences of concern (Table 3).  The International Consortium 
for Polynucleotide Synthesis (ICPS) developed a plan for creating an 
effective oversight framework for the DNA synthesis industry.
108
  A 
rival German effort, led by the International Association of Synthetic 
Biology (IASB), developed a code of conduct for assessing the safety 
of DNA sequence orders that would rely on both (1) automated 
searches for matches with sequences of concern (e.g., the U.S. list of 
sequences of concern) and (2) human double-checking.
109
 The 
International Gene Synthesis Consortium (IGSC), comprised of the 
world's leading gene synthesis companies, established a harmonized 
protocol for preventing the misuse of gene synthesis.
110
  In addition, 
the U.S. Department of Health and Human Services (HHS) issued 
guidance aimed at reducing the risk that synthetic DNA will be 
misused deliberately to create dangerous organisms.
111
  Efforts to 
articulate and refine biosecurity standards for dual-use research in 
synthetic biology and other life science fields are ongoing.
112
 
 
 
 
 
 106. Stephen M. Maurer, End of the Beginning or Beginning of the End? Synthetic 
Biology’s Stalled Security Agenda and the Prospects for Restarting It, 45 VAL. U. L. REV. 1387 
(2011). 
 107. Michele S. Garfinkel et al., Synthetic Genomics: Options for Governance, 5 
BIOSECURITY & BIOTERRORISM, 359 (2007). 
 108. Bügl, supra note 15. 
 109. The IASB Code of Conduct for Best Practices in Gene Synthesis, INTERNATIONAL 
ASSOCIATION SYNTHETIC BIOLOGY (Nov. 3, 2009), http://www.ia-sb.eu/tasks/sites/synthetic-
biology/assets/File/pdf/iasb_code_of_conduct_final.pdf. 
 110. Harmonized Screening Protocol: Gene Sequence and Customer Screening to 
Promote Biosecurity, INTERNATIONAL GENE SYNTHESIS CONSORTIUM (IGSC) (November 18, 
2009), http://www.genesynthesisconsortium.org/resources.php. 
 111. Dep’t of Health and Human Servs., supra note 17. 
 112. See, e.g., Enhancing Responsible Science: Considerations for the Development and 
Dissemination of Codes of Conduct for Dual Use Research, NAT’L SCI. ADVISORY BD. ON 
BIOSECURITY (NSABB), 
http://oba.od.nih.gov/oba/biosecurity/documents/COMBINED_Codes_PDFs.pdf (last visited 
Feb. 19, 2014). 
TORRANCE & KAHL   4/2/2014  11:00 PM 
220 SANTA CLARA HIGH TECH. L.J. [Vol. 30 
Table 3. Biosecurity Standards in Synthetic Biology 
 
Standards Setting 
Organization 
Year 
started 
Biosecurity Standards 
The International 
Consortium for 
Polynucleotide 
Synthesis (ICPS) 
2007 The ICPS developed a plan for creating 
an effective oversight framework for the 
DNA synthesis industry. 
International 
Association of 
Synthetic Biology 
(IASB) 
2008 The IASB established a code of conduct 
for best practices in gene synthesis, 
which is primarily based on a self-
policed system among gene synthesis 
and assembly firms. 
International Gene 
Synthesis 
Consortium 
(IGSC) 
2009 The IGSC developed a harmonized 
protocol for gene sequence and customer 
screening to prevent the misuse of gene 
synthesis.  
U.S. Department 
of Health and 
Human Services 
(HHS) 
2010 The HHS recommendations include 
screening customers as well as DNA 
sequences, follow-up screening as 
necessary, and consulting with U.S. 
government contacts as needed. 
D. Legal Standards Setting 
The development of legal standards to enable synthetic biology 
researchers to use and share biological parts was first proposed by 
Drew Endy in 2005.
113
  Over several years beginning late in 2008, the 
BioBricks Foundation developed a two-part legal agreement designed 
to standardize the use and contribution of biological parts, collectively 
referred to as the BioBrick Public Agreement (BPA).
114
  The 
BioBrick User Agreement is designed to oblige signors to abide by a 
set of rules for using biological parts responsibly.  The BioBrick 
Contributor Agreement is designed to govern the responsible 
contribution of biological parts for others to use.  The BPA purports 
to impose a legal standard on users and contributors of genetically 
encoded functions, and includes provisions on attribution, safety, and 
 
 113. Endy, supra note 3, at 450 (“[L]egal standards are needed to define means by which 
large collections of parts encoding basic biological functions, from a myriad of sources, can be 
easily shared and used in combination to realize many applications.”). 
 114. The BioBrick Public Agreement (BPA), BIOBRICKS FOUNDATION, 
https://biobricks.org/bpa/ (last visited Feb. 19, 2014).  For purposes of full disclosure, the 
authors wish to note that Andrew W. Torrance contributed to early drafts of the BPA at the 
invitation of the BioBricks Foundation. 
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intellectual property rights.
115
  Of special note, contributors who sign 
the BioBrick Contributor Agreement promise not to assert any 
existing or future intellectual property rights they possess to any parts 
they contribute under the contract.
116
 
III. INTELLECTUAL PROPERTY AND SYNTHETIC BIOLOGY 
STANDARDS 
Four principle types of intellectual property protection are 
relevant to the protection of synthetic biology inventions: (1) patent, 
(2) trade secrecy, (3) copyright, and (4) trademark.  Thus far, only 
patent and trade secrecy have played substantial roles in protecting 
such inventions, though both copyright and trademark have been 
suggested.
117
  The subject matter protectable by patent or trade 
secrecy is broad, spanning such innovations as new DNA, RNA, 
polypeptide molecules, genomes, cells, organisms, and a myriad of 
methods of using them either singly or in combination.  Because trade 
secrets are, by their very nature, difficult to catalogue, the discussion 
here focuses on patents.  Patent protection for DNA molecules, such 
as those deposited into the iGEM Registry of Standard Biological 
Parts and other publicly available registries of biological parts, will 
serve as an additional focus, though the patent law principles 
discussed are applicable to other products and methods of synthetic 
biology. 
A. Patent 
The United States Patent and Trademark Office has granted 
patents claiming isolated or purified DNA molecules since at least the 
1970s.
118
  The 1990s race to sequence the entire human genome 
precipitated a flood of patent applications (many later maturing into 
patents) claiming human DNA that peaked around 2000.
119
  Patenting 
DNA has been criticized as being unethical
120
 and for causing a 
 
 115. Id. 
 116. See Contributors, BIOBRICKS FOUNDATION, https://biobricks.org/bpa/contributors/ 
(last visited Feb. 19, 2014). 
 117. Andrew W. Torrance, Synthesizing Law for Synthetic Biology, 11 MINN. J. L. SCI. & 
TECH. 629 (2010). 
 118. Andrew W. Torrance, Gene Concepts, Gene Talk, and Gene Patents, 11 MINN. J. L. 
SCI. & TECH. 157 (2010). 
 119. Id. 
 120. Tom Hollon, NIH Researchers Receive Cut-Price BRCA Test, 6 NAT. MED. 610 
(2000). 
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genetic “tragedy of the anticommons.”121  By one account, roughly 
20% of known human genes are claimed in a U.S. patent.
122
  
Although a recent empirical study has brought this estimate into 
question,
123
 if such assessments are even somewhat accurate, 
synthetic biologists may be at substantial risk of infringing prodigious 
numbers of patent claims to DNA sequences.  As such, existing patent 
rights may encumber the products and methods of synthetic biology. 
Since at least 2005, uncertainty has been rising about whether or 
not isolated or purified natural-source DNA constitutes legitimate 
patentable subject matter.  In 2005, a Court of Appeals for the Federal 
Circuit panel held that a set of patent claims expressing sequence tags 
(ESTs) lacked utility and enablement, casting doubt on the 
patentability of partial-gene DNA sequences.
124
  In 2007, Xavier 
Becerra (Democrat Congressman from California) and Dave Weldon 
(Republican Congressman from Florida) unsuccessfully championed 
passage of the Genomic Research and Accessibility Act.
125
  Section 
106 of this Act would have barred genes from patent eligibility, 
stipulating that “[n]otwithstanding any other provision of law, no 
patent may be obtained for a nucleotide sequence, or its functions or 
correlations, or the naturally occurring products it specifies.”126  
Although this proposal has never been passed by the U.S. Congress, 
Section 33 of the Leahy-Smith America Invents Act of 2011 did 
amend U.S. patent law to ban the patentability of any invention 
“directed to or encompassing a human organism.”127  Lacking 
legislative history, court interpretation, and formal incorporation into 
the U.S. Code, it is as yet unclear what legal influence Section 33 may 
have on the patentability of human DNA sequences. 
Most relevant to synthetic biology is the litigation initiated in 
2009 by the American Civil Liberties Union (ACLU) and its allies 
against the biotechnology firm Myriad Genetics, Inc. and the United 
States Patent and Trademark Office.
128
  Myriad Genetics, Inc. owns 
 
 121. Michael A. Heller & Rebecca S. Eisenberg, Can Patents Deter Innovation? The 
Anticommons in Biomedical Research, 280 SCIENCE 698 (1998). 
 122. Kyle Jensen & Fiona Murray, Intellectual Property Landscape of the Human 
Genome, 310 SCIENCE 239 (2005). 
 123. Christopher M. Holman, Debunking the Myth that Whole-Genome Sequencing 
Infringes Thousands of Gene Patents, 30 NAT. BIOTECHNOL. 240 (2012). 
 124. In re Fisher, 421 F.3d 1365 (Fed. Cir. 2005). 
 125. Genomic Research and Accessibility Act, H.R. 977, 110th Cong. (1st Sess. 2007). 
 126. Id. 
 127. Leahy-Smith America Invents Act, Pub. L. No. 112-29, 125 Stat. 284, 340 (2011). 
 128. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Off., 669 F. Supp. 2d 365 
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rights to several patents claiming, among other inventions, human 
BRCA1 and BRCA2 gene variants predictive of breast and ovarian 
cancer.
129
  In its initial complaint in an action for declaratory 
judgment, the ACLU stated its opposition to the patent-eligibility of 
human genes, and challenged “the legality and constitutionality of 
granting patents over this most basic element of every person’s 
individuality.”130  In March 2010, Judge Sweet, of the Southern 
District of New York, decided that genes “containing sequences 
found in nature . . . are deemed unpatentable subject matter.”131  
Myriad appealed the decision to the Federal Circuit.  On July 29, 
2011, a panel of three judges largely reversed the lower court, and 
restored the patentability of DNA.
132
 
In response, the ACLU filed a petition for a writ of certiorari to 
the U.S. Supreme Court, which vacated the Federal Circuit’s decision 
on March 26, 2012,
133
 and instructed that court to reconsider the 
patentability issues in light of Mayo v. Prometheus, a patentability 
decision the Court had made a week before.
134
  The patent claims at 
issue in Mayo v. Prometheus were directed to methods of diagnosis 
using human metabolites, not to DNA molecules per se.
135
  However, 
the Supreme Court clearly signaled its discontent with the Federal 
Circuit’s panel decision.136  On August 16, 2012, the same panel of 
Federal Circuit judges broadly reaffirmed their earlier panel decision, 
again upholding the patent-eligibility of isolated DNA.
137
  The Court 
of Appeals for the Federal Circuit declined to reconsider the panel 
decision by rehearing the case en banc, and the case arrived again 
 
(S.D.N.Y. 2009). 
 129. See, e.g., U.S. Patent No. 5,709,999 (filed Mar. 1995), U.S. Patent No. 5,747,282 
(filed June 7, 1995), U.S. Patent No. 5,753,441 (filed Jan. 5, 1996), U.S. Patent No. 5,837,492 
(filed Apr. 29, 1996), U.S. Patent No. 6,033,857 (filed Mar. 20, 1998), U.S. Patent No. 
5,654,155 (filed Feb. 12, 1996), U.S. Patent No. 5,750,400 (filed Feb. 12, 1997), U.S. Patent No. 
6,051,379 (filed Dec. 2, 1997), U.S. Patent No. 6,951,721 (filed Aug. 8, 2001), U.S. Patent No. 
7,250,497 (filed June 9, 2003), U.S. Patent No. 6,083,698 (filed Dec. 11, 1997). 
 130. Complaint at 1, Ass’n for Molecular Pathology v. U.S. Patent & Trademark Off., 669 
F. Supp. 2d 365 (S.D.N.Y. 2009) (No. 09CV04515). 
 131. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Off., 702 F. Supp. 2d 
181, 185 (S.D.N.Y. 2010). 
 132. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Off., 653 F.3d 1329 (Fed. 
Cir. 2011). 
 133. Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 132 S. Ct. 1794 (2012). 
 134. Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289 (2012). 
 135. Id. at 1295. 
 136. See id. at 1302-03. 
 137. Ass’n for Molecular Pathology v. U.S. Patent & Trademark Off., 669 F. Supp. 2d, 
365 (S.D.N.Y. 2009). 
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before the Supreme Court.
138
  Oral arguments were heard on April 15, 
2013, and the Supreme Court issued a decision on June 13, 2013 
holding natural, unmodified DNA—even when isolated or purified 
from a genome—to be subject matter ineligible for patent 
protection.
139
  Together, the Mayo v. Prometheus and AMP v. Myriad 
decisions have rendered nonsynthetic DNA and many of its uses 
unpatentable. 
Today, most existing patents directed to DNA molecules claim 
nucleotide sequences identical or similar to those derived from 
naturally occurring genomes.  As the cost, speed, and accuracy of 
DNA synthesis technology continues to improve, the design and 
production of synthetic DNA molecules from nucleotide sequences 
created through computer-aided design processes may become more 
prominent.  Even though the AMP v. Myriad decision has rendered 
natural-source DNA unpatentable, human-designed synthetic DNA is 
likely to remain patent-eligible.  In an amicus curiae brief filed before 
the first Court of Appeals for the Federal Circuit panel decision, the 
U.S. Department of Justice argued that “isolated but otherwise 
unaltered genomic DNA is not patent-eligible subject matter under 35 
U.S.C. Section 101,”140 but that DNA molecules that are “the 
synthetic results of scientists’ manipulation of the natural laws of 
genetics” could be patent-eligible.141 The Supreme Court largely 
adopted this reasoning in its AMP v. Myriad decision.
142
  It is 
important to note, however, that the decision addressed only whether 
isolated DNA or cDNA molecules constitute patentable subject matter 
under 35 U.S.C. Section 101.  The Court specifically expressed no 
opinion whether cDNA molecules satisfy the other statutory 
requirements for patentability such as novelty, non-obviousness, or 
enablement/definiteness under 35 U.S.C. Sections 102, 103, and 
112.
143
 
Although thousands of patent claims to natural, unmodified 
DNA sequences are now firmly in the public domain, there is a strong 
prospect that human-designed synthetic DNA will remain patent-
eligible for the foreseeable future.  The full impact of the AMP v. 
 
 138. Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107 (2013). 
 139. Id. 
 140. Brief for the United States as Amicus Curiae in Support of Neither Party, Ass’n for 
Molecular Pathology v. U.S. Patent & Trademark Off., 653 F.3d 1329 (Fed. Cir. 2011) (No. 
2010-1406). 
 141. Id. at 15. 
 142. Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107 (2013). 
 143. Id. 
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Myriad decision, particularly concerning the validity of patent claims 
to synthetic DNA and its uses, will become more apparent as the 
lower courts interpret this decision in subsequent cases. 
B. Trade Secrecy 
Many owners choose to keep the details, or even the very 
existence, of their intellectual property secret.  Some information is 
difficult to protect by trade secrecy, particularly products or services 
whose intellectual property is self-disclosing.  For example, it would 
be difficult to maintain secrecy about the nucleotide sequence of a 
synthetic DNA construct due to the ease of reverse engineering that 
construct using routine DNA sequencing methods followed by DNA 
synthesis.  By contrast, trade secrets inherent in a protein product 
whose desired functioning depended on a particular folding pattern 
would be easier to preserve due to the great difficulty in reverse 
engineering tertiary and quaternary structure.
144
  By the very nature of 
this form of intellectual property protection, little is known about the 
extent of reliance on trade secrecy across industries or technological 
fields, in general, or in synthetic biology, in particular. 
In a confluence of patent and trade secrecy law, Section 273 of 
the Leahy-Smith America Invents Act added a defense to patent 
infringement for prior commercial use of an invention claimed in a 
patent not owned by a university.
145
  This defense is available only for 
commercial uses,
146
 though the patent statute defines such uses to 
include premarketing regulatory review
147
 and nonprofit laboratory 
uses.
148
  Since this amendment to U.S. patent law has yet to be 
interpreted by the courts, it is unclear how it might affect patents and 
trade secrets in the field of synthetic biology.  Nevertheless, it appears 
to place a modest limit on how patent rights may affect long-standing 
commercial and research uses of synthetic biological products and 
processes. 
 
 144. The Biologics Price Competition and Innovation Act of 2009, passed as part of the 
Patient Protection and Affordable Care Act of 2010, allows the developer of a biologic to 
maintain regulatory data exclusivity for at least 12 years after the biologic is licensed by the 
FDA.  See 42 U.S.C.A. § 262 (West 2014).  Specifically, Section 262 grants biologics 
developers a new form of data-based exclusive rights in exchange for potential loss of patent 
term caused by entry into the market of generic biologics competitors.  Id. 
 145. See Leahy-Smith America Invents Act, Pub. L. No. 112-29, 125 Stat. 284, 297-98 
(2011). 
 146. Id. 
 147. Id. 
 148. Id. 
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C. Copyright 
Copyright protection is relevant to standards development in 
synthetic biology in several respects.  The documents created to 
describe technical standards, such as those of the BioBricks 
Foundation’s RFC process, are subject to copyright protection.  
Software tools developed for synthetic biology applications, including 
the SBOL standard, also are subject to copyright protection.  A third 
way in which copyright protection may be relevant to standards 
development in synthetic biology is the potential for copyright 
protection of DNA sequences. 
Copyright eligibility for DNA sequences has been discussed for 
many years.
149
  Though not all scholars agree, the case has been made 
that synthetic DNA sequences may be especially strong candidates for 
copyright protection, in part because the deliberate design of 
nucleotide sequences allows considerable scope for creative 
expression.
150
  For example, when Synthetic Genomics synthesized 
the first mycoplasma genome, it included several decipherable 
sentences among within the genome.
151
  At least one firm has already 
asserted copyright protection for synthetic DNA sequences,
152
 
although to date there has been no litigation. 
Copyright affords legal protection against unauthorized copying 
for “original works of authorship fixed in any tangible medium of 
expression, now known or later developed”.153  In addition to 
conventional targets for protection, such as books and paintings, 
copyright law has proved capable of adapting to cover additional 
forms of creative expression like architecture and computer 
 
 149. Duncan M. Davidson, Common Law, Uncommon Software, 47 U. PITT. L. REV. 1037, 
1104-05 (1986); Irving Kayton, Copyright in Living Genetically Engineered Works, 50 GEO. 
WASH. L. REV. 191 (1982); Donna Smith, Comment, Copyright Protection for the Intellectual 
Property Rights to Recombinant Deoxyribonucleic Acid: A Proposal, 19 ST. MARY’S L.J. 1083, 
1096-1108 (1988); Dan L. Burk, Copyrightability of Recombinant DNA Sequences, 29 
JURIMETRICS J. 469, 531-32 (1989); Andrew W. Torrance, DNA Copyright, 46 Val. U. L. 
REV. 1, (2011); Christopher M. Holman, Copyright for Engineered DNA: An Idea Whose Time 
Has Come?, 113 W. VA. L. REV. 699 (2011). 
 150. See, e.g., Torrance, supra note 149, at 30. 
 151. Daniel G. Gibson et al., One-Step Assembly in Yeast of 25 Overlapping DNA 
Fragments to Form a Complete Synthetic Mycoplasma genitalium Genome, 105 PNAS 20404 
(2008). 
 152. Illumina, Inc. asserts copyright protection for some of the oligonucleotide primers 
compatible with its DNA sequencing machines in a letter it has sent to customers.  Letter from 
Illumina, Inc. to Illumina, Inc. customers (Sept. 7, 2012), available at 
http://supportres.illumina.com/documents/myillumina/6378de81-c0cc-47d0-9281-
724878bb1c30/2012-09-18_illuminacustomersequenceletter.pdf (last visited March 4, 2014). 
 153. 17 U.S.C. § 102 (2012). 
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software.
154
  Like patent protection, copyright protection for DNA 
sequences originating in naturally occurring genomes is least 
justifiable.  The case for copyright protection would likely strengthen 
as a DNA sequence of interest acquired more characteristics of human 
design and synthetic production.  Of course, the case for copyright 
protection would be far weaker for DNA sequences designed using 
directed evolution approaches since DNA sequences would evolve as 
a consequence of natural selective processes and not as a result of 
DNA sequence design by human authors.
155
 
Copyright eligibility for DNA sequences, were it available, 
would create a much quicker and cheaper route to protection than 
does patent protection, and the resulting protection could last almost 
an order of magnitude longer.  On the other hand, doctrines such as 
fair use could permit more uses by others—especially for purposes of 
scholarship or education—of copyrighted DNA sequences than does 
patent protection, and a DNA copyright framework might allow the 
application of open source principles to synthetic biology.
156
  Now 
that natural-source DNA molecules have lost their eligibility for 
patent protection, copyright stands ready to provide an existing 
alternative form of protection.  Nevertheless, copyright eligibility for 
DNA sequences remains uncertain and untested. 
D. Trademark 
Trademark protection may be available for a mark that indicates 
a single origin for goods or services bearing that mark.
157
  Trademark 
law imposes few restrictions on eligible subject matter, as long as the 
mark achieves its purpose as an indicator of origin, and customer 
confusion is avoided.
158
  Even synthetic DNA sequences might 
qualify as trademarks if they were used in commerce, and served as 
designations of origin for products or services. 
 
 154. 17 U.S.C. § 101 (2012); 17 U.S.C. § 117 (2012). 
 155. Directed evolution, like natural evolution, involves the mutation of nucleic acid 
sequences followed by the selection for variants that display desirable phenotypes.  See Ryan E. 
Cobb, Tong Si & Huimin Zhao, Directed Evolution: An Evolving and Enabling Synthetic 
Biology Tool, 16 CURRENT OPINION CHEM. BIOL. 285 (2012) (describing advances in the use of 
directed evolution in synthetic biology). 
 156. Note that, as with open source software code, coexistent patent rights could still 
create risks of infringement for making, using, selling, offering to sell, or importing synthetic 
DNA sequences. 
 157. See, e.g., ROBERT P. MERGES, PETER S. MENELL & MARK A. LEMLEY, 
INTELLECTUAL PROPERTY IN THE NEW TECHNOLOGICAL AGE 735-36 (5th ed. 2010). 
 158. Id. 
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The BioBricks Foundation has registered “BioBrick” as a U.S. 
trademark.
159
  Currently, the BioBricks Foundation may use this 
trademark as a mild form of leverage to support its standards.  In 
relevant part, Section 3(a) of the BioBrick User Agreement requires 
that “User agrees not to remove or alter any BioBrick identification 
tag included in the Materials . . . .”160  The BioBrick Contributor 
Agreement defines this aspect of the “Materials” in its preamble as 
“the particular standardized genetic material(s) . . . and any associated 
sequence . . . information,” and Section 2 of the BioBrick Contributor 
Agreement requires contributors to allow the addition of a 
“BioBrick™ identification tag” to any genetic material they 
contribute.
161
  If desired, the BioBricks Foundation could assert its 
trademark rights more vigorously to promote its BioBrick-related 
standards by restricting the descriptor “BioBrick” to only those DNA 
molecules fully conforming to specified standards. 
E. Synthetic Biology, Biotechnology, and Intellectual Property 
Many of the intellectual property issues that arise in specific 
context of synthetic biology also pertain to the broader field of 
biotechnology.  However, synthetic biology differs in its reliance on 
approaches from engineering and computer science, including an 
emphasis on standards.  Due to their unique features, some synthetic 
biological inventions may be eligible not only for patent protection, 
but also for copyright, and even trademark, protection.  Innovations in 
synthetic biology may become subject to complicated policy debates 
about which forms of intellectual property protection are most 
appropriate, just as innovations in software were a generation ago.
162
  
As such, it is important to address the potential confusion surrounding 
intellectual property issues in synthetic biology, particularly with 
 
 159. “BioBrick” is a registered trademark of the BioBricks Foundation  See BIOBRICK, 
Registration No. 3836261.  It is registered in international classes 41 and 42.  Id.  Its description 
in class 42 is “Research and development services in the fields of biology and biological 
engineering; providing information in the fields of biology and biological engineering.”  Id. 
 160. The BioBrick User Agreement, BIOBRICKS FOUNDATION, 
https://biobricks.org/bpa/users/agreement/ (last visited Jan. 31, 2014) (“User agrees not to 
remove or alter any BioBrick™ identification tag or data included in the Materials . . . .”). 
 161. The BioBrick Contributor Agreement, BIOBRICKS FOUNDATION, 
http://biobricks.org/wp-content/themes/bbf/bpa-sample.php (last visited Jan. 31, 2014) 
(“Contributor agrees that Materials may be modified to include a BioBrick™ identification 
tag . . . .”). 
 162. Arti Rai & James Boyle, Synthetic Biology: Caught between Property Rights, the 
Public Domain, and the Commons, PLOS BIOL. (March 13, 2007), 
http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.0050058. 
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regards to standards setting initiatives.  This must be done in order to 
avoid the prolonged uncertainty that could undermine the necessary 
commercial investment for bringing useful synthetic biology 
applications to market. 
CONCLUSIONS 
There has been considerable discussion and activity surrounding 
standards setting in synthetic biology.  This may be due, in part, to the 
interdisciplinary backgrounds of many of the field’s leading 
participants.  A number of institutions within synthetic biology have 
made standards setting a priority, and many standards have been 
proposed, including those pertaining to the structure, function, and 
description of genetic components, data sharing, biosecurity, and law.  
Despite this interest in standards, progress in standards setting has 
been quite modest so far.  Standards for physical assembly of DNA 
fragments are continuing to evolve, and methods such as Gibson 
Assembly and de novo DNA synthesis are gaining acceptance as 
alternate approaches for the construction of large DNA molecules. 
Moreover, standards for other technical aspects of synthetic biology 
have begun to emerge, including functional composition standards 
that support the ability of assembled biological parts to function in a 
predictable manner, standards for units of measurement, and data 
exchange standards.  At the present time, standardization efforts do 
not appear to have impeded innovation in synthetic biology and no 
single technical standard appears to have dominated the field of 
synthetic biology.  By comparison, standards covering policies in 
biosecurity appear to be better established, and a U.S. government-
proposed biosecurity guidance governing commercial orders for 
synthetic DNA has been widely adopted. 
Patent rights that encumber components and methods have long 
been a concern among those in synthetic biology, especially as a 
perceived threat to the field’s prominent ethos of open biological 
innovation.  Currently, there is little evidence that patent rights 
adversely affect synthetic biological research.  In fact, the patent-
eligibility of natural-source DNA molecules has now been ended by 
the Supreme Court in its AMP v. Myriad decision, and the new AIA 
has created a broadened defense of prior commercial use that offers 
some protection from patent infringement for some uses of synthetic 
biological products and processes.  Copyright and trademark may 
provide alternatives mechanisms for conferring rights in synthetic 
biological inventions, setting and reinforcing standards, or promoting 
open innovation.  Among the standards-setting groups that have 
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formed within the synthetic biology community, most have expressed 
a preference that standards remain open and accessible to the 
community as a whole.  This preference, however, has not yet been 
incorporated into formal policies requiring the disclosure and 
licensing of intellectual property rights covering technical standards.  
Whether such policies could be made mandatory or would ultimately 
be beneficial to the field of synthetic biology remain open questions.  
What is certain is that the synthetic biology community is unusually 
attuned to debates surrounding intellectual property and standards 
setting, and views its engagement in these debates as vital to ensure 
the continued success of synthetic biology. 
